QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • Neurocrine Biosciences’ (NBIX) VMAT2 Program to Move Into Phase II Clinical Trials 0 comments
    Oct 19, 2010 1:47 PM | about stocks: NBIX

    Yesterday, Neurocrine Biosciences Inc., a biopharmaceutical company that specializes in neurological and endocrine diseases and disorders, announced that it passed its second Phase I clinical trial of its compound NBI-98854, a drug that inhibits VMAT2. The successful testing on healthy volunteers means Neurocrine can proceed with Phase II testing.

    VMAT2 is a protein found in the human brain that is responsible for moving monoamines (chemicals like dopamine, norepinephrine, serotonin, and histamine) to nerve cells. NBI-98854 is a new kind of VMAT2 inhibitor that measures dopamine release to nerves, while having a minimal effect on the other kinds of monoamines in the brain, reducing negative side effects from the medication.

    With the successful completion of the Phase IIa study, Neurocrine plans to file with the FDA an Investigational New Drug application to move on to Phase IIb studies in patients with the disorder Tardive Dyskinesia. NBI-98854 may prove helpful in treating other neurological disorders as well, including schizophrenia and Tourette’s syndrome.

    “Our VMAT2 inhibitor was well tolerated and again showed us the desired pharmacokinetic and safety profiles after repeated dosing in healthy volunteers,” said Christopher F. O’Brien, Chief Medical Officer of Neurocrine Biosciences. “Based on the data set from our Phase I studies, we plan to initiate a Phase IIa dose exploration study in Tardive Dyskinesia patients by year end.”

    Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net

    Disclosure: no positions

    Stocks: NBIX
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.